Your browser doesn't support javascript.
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models.
Lambe, Teresa; Spencer, Alexandra J; Thomas, Kelly M; Gooch, Karen E; Thomas, Stephen; White, Andrew D; Humphries, Holly E; Wright, Daniel; Belij-Rammerstorfer, Sandra; Thakur, Nazia; Conceicao, Carina; Watson, Robert; Alden, Leonie; Allen, Lauren; Aram, Marilyn; Bewley, Kevin R; Brunt, Emily; Brown, Phillip; Cavell, Breeze E; Cobb, Rebecca; Fotheringham, Susan A; Gilbride, Ciaran; Harris, Debbie J; Ho, Catherine M K; Hunter, Laura; Kennard, Chelsea L; Leung, Stephanie; Lucas, Vanessa; Ngabo, Didier; Ryan, Kathryn A; Sharpe, Hannah; Sarfas, Charlotte; Sibley, Laura; Slack, Gillian S; Ulaszewska, Marta; Wand, Nadina; Wiblin, Nathan R; Gleeson, Fergus V; Bailey, Dalan; Sharpe, Sally; Charlton, Sue; Salguero, Francisco J; Carroll, Miles W; Gilbert, Sarah C.
  • Lambe T; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Spencer AJ; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Thomas KM; National Infection Service, Public Health England, Salisbury, UK.
  • Gooch KE; National Infection Service, Public Health England, Salisbury, UK.
  • Thomas S; National Infection Service, Public Health England, Salisbury, UK.
  • White AD; National Infection Service, Public Health England, Salisbury, UK.
  • Humphries HE; National Infection Service, Public Health England, Salisbury, UK.
  • Wright D; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Belij-Rammerstorfer S; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Thakur N; The Pirbright Institute, Woking, Surrey, UK.
  • Conceicao C; The Pirbright Institute, Woking, Surrey, UK.
  • Watson R; National Infection Service, Public Health England, Salisbury, UK.
  • Alden L; National Infection Service, Public Health England, Salisbury, UK.
  • Allen L; National Infection Service, Public Health England, Salisbury, UK.
  • Aram M; National Infection Service, Public Health England, Salisbury, UK.
  • Bewley KR; National Infection Service, Public Health England, Salisbury, UK.
  • Brunt E; National Infection Service, Public Health England, Salisbury, UK.
  • Brown P; National Infection Service, Public Health England, Salisbury, UK.
  • Cavell BE; National Infection Service, Public Health England, Salisbury, UK.
  • Cobb R; National Infection Service, Public Health England, Salisbury, UK.
  • Fotheringham SA; National Infection Service, Public Health England, Salisbury, UK.
  • Gilbride C; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Harris DJ; National Infection Service, Public Health England, Salisbury, UK.
  • Ho CMK; National Infection Service, Public Health England, Salisbury, UK.
  • Hunter L; National Infection Service, Public Health England, Salisbury, UK.
  • Kennard CL; National Infection Service, Public Health England, Salisbury, UK.
  • Leung S; National Infection Service, Public Health England, Salisbury, UK.
  • Lucas V; National Infection Service, Public Health England, Salisbury, UK.
  • Ngabo D; National Infection Service, Public Health England, Salisbury, UK.
  • Ryan KA; National Infection Service, Public Health England, Salisbury, UK.
  • Sharpe H; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Sarfas C; National Infection Service, Public Health England, Salisbury, UK.
  • Sibley L; National Infection Service, Public Health England, Salisbury, UK.
  • Slack GS; National Infection Service, Public Health England, Salisbury, UK.
  • Ulaszewska M; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wand N; National Infection Service, Public Health England, Salisbury, UK.
  • Wiblin NR; National Infection Service, Public Health England, Salisbury, UK.
  • Gleeson FV; Department of Oncology, University of Oxford, Oxford, UK.
  • Bailey D; The Pirbright Institute, Woking, Surrey, UK.
  • Sharpe S; National Infection Service, Public Health England, Salisbury, UK.
  • Charlton S; National Infection Service, Public Health England, Salisbury, UK.
  • Salguero FJ; National Infection Service, Public Health England, Salisbury, UK.
  • Carroll MW; National Infection Service, Public Health England, Salisbury, UK.
  • Gilbert SC; Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Commun Biol ; 4(1): 915, 2021 07 26.
Article in English | MEDLINE | ID: covidwho-1327224
ABSTRACT
Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines against SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment of this phenomena is warranted for vaccine development against SARS CoV-2. Here we report detailed immune profiling after ChAdOx1 nCoV-19 (AZD1222) and subsequent high dose challenge in two animal models of SARS-CoV-2 mediated disease. We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. In a second animal model, ferrets, ChAdOx1 nCoV-19 reduced both virus shedding and lung pathology. Antibody titre were boosted by a second dose. Data from these challenge models on the absence of enhanced disease and the detailed immune profiling, support the continued clinical evaluation of ChAdOx1 nCoV-19.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: Commun Biol Year: 2021 Document Type: Article Affiliation country: S42003-021-02443-0

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: Commun Biol Year: 2021 Document Type: Article Affiliation country: S42003-021-02443-0